Skip to main content
OpenTrials
Completed

NCT Number: NCT01585974

Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Many Locations, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • To be diagnosed as metastatic renal cell carcinoma
  • Previous cytokine therapy
  • To sign informed consent form (ICF)

Exclusion criteria

  • Patients not willing to sign informed consent form or who withdraw their consent

Treatment and study plan

No intervention

Other

All dosage, frequency and duration for drugs will be under the decision of the treating physician

Primary outcomes

  1. Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product

    Time frame: After 2 years

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAE)

    Time frame: After 2 years

  2. Change of Tumor status

    Time frame: Baseline and 2 years

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma

Acronym: TURCOS

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Apr 26, 2012
Registry last updated
Oct 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.